A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations

NCT05560334 · clinicaltrials.gov ↗
PHASE2
Phase
UNKNOWN
Status
20
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

Tianjin Medical University Cancer Institute and Hospital